<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03711110</url>
  </required_header>
  <id_info>
    <org_study_id>CARTIER</org_study_id>
    <nct_id>NCT03711110</nct_id>
  </id_info>
  <brief_title>Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)</brief_title>
  <acronym>CARTIER</acronym>
  <official_title>Cardiotoxicity in the Elderly. Comparative Clinical Trial Between Primary Versus Secondary Cardiovascular Prevention Strategies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigación Biomédica de Salamanca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CARTIER study is a randomized, multicenter, open-label clinical trial comparing, in
      elderly patients with cancer under anti-tumoral treatment, two different cardiotoxicity
      prevention strategies: primary (intensive cardiovascular monitoring focused on prevention and
      early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams
      involved in cancer patient care) vs. secondary (current clinical practice where intensive
      cardiovascular monitoring is not routinely performed and cardiotoxicity patient care is based
      on the onco-hematologist criteria).

      The primary endpoint is to determine whether this primary prevention englobing cardiovascular
      monitoring plus intensive multidisciplinary management is superior to the current clinical
      practice in reducing all cause mortality.

      Other secondary objectives of the study are to analyze the impact of this intensive
      cardiovascular monitoring strategy on the incidence of cardiovascular mortality, oncological
      mortality, hospitalization and/or urgent care due to cardiovascular complications,
      hospitalization and/or urgent oncological care due to cancer complications, tumor progression
      and cost-effectiveness analysis.

      A total of 514 patients ≥ 65 years old diagnosed with any of the following onco-hematological
      cancers, colon, breast, lymphoma, chronic lymphoma leukemia, chronic myeloid leukemia or
      myeloma, undergoing standardized anti-tumoral treatment, will be recruited.

      The incidence of primary and secondary outcomes will be measured at 2 and 5 years
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, multicenter, open-label clinical trial comparing, in elderly patient with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Two (mid-term analysis) and five years of follow-up</time_frame>
    <description>Cumulative incidence of all-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oncological mortality</measure>
    <time_frame>Two and five years of follow-up</time_frame>
    <description>Cumulative incidence of oncological mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>Two and five years of follow-up</time_frame>
    <description>Cumulative incidence of cardiovascular mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>Two and five years of follow-up</time_frame>
    <description>Cumulative incidence of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization/emergency cardiovascular cause</measure>
    <time_frame>Two and five years of follow-up</time_frame>
    <description>Cumulative incidence of hospitalization and/or emergency care for cardiovascular cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization/emergency cancer cause</measure>
    <time_frame>Two and five years of follow-up</time_frame>
    <description>Cumulative incidence of hospitalization and/or emergency care for cancer cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor recurrence or progression</measure>
    <time_frame>Two and five years of follow-up</time_frame>
    <description>Incidence of tumoral recurrence or progression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">514</enrollment>
  <condition>Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)</condition>
  <condition>Elderly</condition>
  <condition>Antineoplastic Agents</condition>
  <condition>Cardiotoxicity</condition>
  <arm_group>
    <arm_group_label>Primary prevention strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secondary prevention strategy (control)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Current clinical practice: cardiac care is based on the onco-hematologist criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intensive cardiovascular monitoring</intervention_name>
    <description>Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).
Assessment protocol: Anamnesis and physical examination; EKG; Echocardiogram; Biomarkers (troponin and natriuretic peptide); Structured counselling on healthy cardiac practices; Treatment optimization of cardiovascular risk factors and heart diseases; Quality of life (ECOG Performance status and Minnesota questionnaires); Interaction and management of patient care by the cardio-onco-hematology team. Moreover, cardiac MRI in centers participating in the CARTIER-MR sub-study.</description>
    <arm_group_label>Primary prevention strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).
Assessment protocol: Anamnesis and physical examination; ECOG Performance status; cardiac patient care based on the onco-hematologist criteria</description>
    <arm_group_label>Secondary prevention strategy (control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 65 years old

          -  Expected survival &gt;1 year

          -  Colon cancer, breast cancer, lymphoma, chronic lymphoma leukemia, chronic myeloid
             leukemia, myeloma

          -  Signature on the informed consent

        Exclusion Criteria:

          -  Patients included in clinical trials will be excluded if they interfere with the
             CARTIER follow-up protocol. If they do not interfere they can be included

          -  Patients who had received previous potentially cardiotoxic anticancer treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro L Sánchez, Ph. D.</last_name>
    <role>Study Director</role>
    <affiliation>IBSAL-Instituto de Investigación Biomédica de Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Martín-García, Ph. D.</last_name>
    <role>Study Director</role>
    <affiliation>IBSAL-Instituto de Investigación Biomédica de Salamanca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro L Sánchez, Ph. D.</last_name>
    <phone>923 291100</phone>
    <phone_ext>55356</phone_ext>
    <email>plsanchez@saludcastillayleon.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Martín-García, Ph. D.</last_name>
    <phone>923 291100</phone>
    <phone_ext>55356</phone_ext>
    <email>amartingarcia@usal.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pilar Mazón-Ramos, MD</last_name>
      <phone>+34 981 950 000</phone>
      <email>pilarmazon@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Pilar Mazón-Ramos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Galdakao-Usansolo</name>
      <address>
        <city>Galdakao</city>
        <state>Vizcaya</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sonia Velasco, MD</last_name>
      <phone>+34 944 007 000</phone>
      <email>soniavelascodelcastillo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sonia Velasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ignacio Ferreira-González, MD</last_name>
      <phone>+34 91 336 80 00</phone>
      <email>nachoferreira@secardiologia.es</email>
    </contact>
    <investigator>
      <last_name>Ignacio Ferreira-González, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dolores Mesa, MD</last_name>
      <phone>+34 957 010 000</phone>
      <email>loladoctora@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dolores Mesa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernando Alfonso-Manterola</last_name>
      <phone>+34 915 202 200</phone>
      <email>falf@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Fernando Alfonso-Manterola, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital G. Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eduardo Zatarain-Nicolás</last_name>
      <phone>+34 915 868 000</phone>
      <email>eduzatanico@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eduardo Zatarain-Nicolás, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Pardo-Sanz, MD</last_name>
      <phone>+34 91 336 80 00</phone>
      <email>anapardosanz0@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana Pardo-Sanz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis F Navarro-del-Amo, MD</last_name>
      <phone>+34 915 504 800</phone>
      <email>fnavarro@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Luis F Navarro-del-Amo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen Jiménez-López-Guarch, MD</last_name>
      <phone>+34 91 390 80 00</phone>
      <email>cjlguarch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Carmen Jiménez-López-Guarch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristina Mitroi, MD</last_name>
      <phone>+34 911 916 565</phone>
      <email>cristina_mitroi@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Cristina Mitroi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan J Gómez-Doblas</last_name>
      <phone>+34 951 032 000</phone>
      <email>jjgomezdoblas@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan J Gómez-Doblas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Martín-García, Ph. D.</last_name>
      <phone>+34 923291100</phone>
      <phone_ext>55356</phone_ext>
      <email>amartingarcia@usal.es</email>
    </contact>
    <investigator>
      <last_name>Ana Martín-García, Ph. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro L Sánchez, Ph. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gonzalo Baron-Esquivias</last_name>
      <phone>+34 955 012 000</phone>
      <email>gonzalo.baron.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Gonzalo Baron-Esquivias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Río Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marina Revilla-Martínez, MD</last_name>
      <phone>+34 983 420 400</phone>
      <email>marinarema@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Marina Revilla-Martínez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiotoxicity</keyword>
  <keyword>Elderly</keyword>
  <keyword>Antineoplastic agents</keyword>
  <keyword>Cardiovascular monitoring</keyword>
  <keyword>Cardioprotection</keyword>
  <keyword>Cardio-oncology</keyword>
  <keyword>Chemically-Induced Disorders</keyword>
  <keyword>Radiation Injuries</keyword>
  <keyword>Drug-Related Side Effects and Adverse Reactions.</keyword>
  <keyword>Primary prevention</keyword>
  <keyword>Secondary prevention.</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

